The Cooper Companies, Inc.
COO
Rank in Stocks
#1914
The Cooper Companies, Inc. (COO) operates as a global medical device firm,... The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Share Price
$58.13
Last synced: 2026-10-19
Market Cap
$11.05B
Change (1 day)
0.33%
Change (1 year)
-22.48%
Country
US
Trade The Cooper Companies, Inc. (COO)
Category
Healthcare
P/E ratio for The Cooper Companies, Inc. (COO)
P/E ratio as of October 2026 TTM: 18.73
According to The Cooper Companies, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.73. At the end of 2024 the company had a P/E ratio of 53.07.
P/E ratio history for The Cooper Companies, Inc. from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 18.73 | -49.78% |
| 2025 | 37.30 | -29.73% |
| 2024 | 53.07 | 1.18% |
| 2023 | 52.45 | 50.14% |
| 2022 | 34.94 | 1,878.19% |
| 2021 | 1.77 | -89.25% |
| 2020 | 16.43 | 113.76% |
| 2019 | 7.69 | -66.09% |
| 2018 | 22.67 | 187.78% |
| 2017 | 7.88 | 1.07% |
| 2016 | 7.79 | -14.15% |
| 2015 | 9.08 | 24.40% |
| 2014 | 7.30 | 37.62% |
| 2013 | 5.30 | 14.51% |
| 2012 | 4.63 | -0.07% |
| 2011 | 4.63 | -7.35% |
| 2010 | 5.00 | 59.02% |
| 2009 | 3.14 | 11.08% |
| 2008 | 2.83 | -106.75% |
| 2007 | -41.94 | -533.01% |
| 2006 | 9.69 | 25.13% |
| 2005 | 7.74 | 27.19% |
| 2004 | 6.09 | 23.42% |
| 2003 | 4.93 | 18.96% |
| 2002 | 4.15 | -13.54% |
| 2001 | 4.79 | 9.50% |
| 2000 | 4.38 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 47.48 | 153.52% |
US
|
|
| 27.43 | 46.42% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | 203.76% |
US
|
|
| - | - |
CH
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.